Loading clinical trials...
Loading clinical trials...
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Florida Cancer Specialists
Sarasota, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic- Minnesota
Rochester, Minnesota, United States
University Of Nebraska Medical Center
Omaha, Nebraska, United States
Cayuga Cancer Center
Ithaca, New York, United States
Northwell Health
Lake Success, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Start Date
May 20, 2025
Primary Completion Date
May 1, 2030
Completion Date
December 1, 2032
Last Updated
March 2, 2026
279
ESTIMATED participants
Pirtobrutinib
DRUG
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT06189391
NCT05006716
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07277231